COVID-19: impact on cancer workforce and delivery of care

Mayor, Susan

doi:10.1016/s1470-2045(20)30240-0

Cited by 92 publications

(108 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, we know that cancer referrals for primary care have dropped very dramatically as both primary and secondary care reorient their focus towards the COVID‐19 epidemic. Clearly, there are difficult decisions to be made over COVID‐19 and ongoing cancer control efforts; it has transformed every aspect of cancer care and has impacted profoundly on the cancer workforce (Mayor, 2020). It has caused many health planners to think carefully about how they can manage cancer through an epidemic such as this; cancer treatments are profoundly impacted and we know that cancer patients, particularly those receiving chemotherapy, are especially vulnerable to COVID‐19—so difficult decisions are needing to be made about treatment decisions for many cancer patients (Al‐Shamsi et al., 2020; Vrdoljak, Sullivan, & Lawler, 2020).…”

mentioning

confidence: 99%

Cancer diagnosis and treatment in the COVID‐19 era

Weller

2020

Eur J Cancer Care

View full text Add to dashboard Cite

mentioning

confidence: 99%

Cancer diagnosis and treatment in the COVID‐19 era

Weller

2020

Eur J Cancer Care

View full text Add to dashboard Cite

“…In order to meet these requirements, some suggestions can be considered, such as changing therapy regimens and limiting patients' visits to the hospital. In particular, some authors recommend less intensive treatment regimens in order to replace the Pembrolizumab regimen of 200 mg three-weekly by 400 mg six-weekly [114]. The main therapy strategies for COVID-19 are aimed at suppressing the over-inflammatory response.…”

Section: Resultsmentioning

confidence: 99%

Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?

et al. 2020

View full text Add to dashboard Cite

Dysregulation of the immune system undoubtedly plays an important and, perhaps, determining role in the COVID-19 pathogenesis. While the main treatment of the COVID-19 intoxication is focused on neutralizing the excessive inflammatory response, it is worth considering an equally significant problem of the immunosuppressive conditions including immuno-paralysis, which lead to the secondary infection. Therefore, choosing a treatment strategy for the immune-mediated complications of coronavirus infection, one has to pass between Scylla and Charybdis, so that, in the fight against the “cytokine storm,” it is vital not to miss the point of the immune silence that turns into immuno-paralysis.

show abstract

“…The patient management of cancer-related symptoms, quality of life, and survival will be disrupted. [18][19][20]…”

Section: The Impacts Of Covid-19 In Cancer Carementioning

confidence: 99%

Multiple Myeloma Management in COVID-19 Era

Kurniawan

Halim

Sutandyo

2021

ASJO

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020. The complexity of handling multiple myeloma (MM) has increased substantially during this pandemic. The objective of this review is to know the current recommendation to manage MM in the COVID-19 era. Methods Electronic databases, including PubMed central and PubMed, were used to conduct a literature search. It was conducted on May 18, 2020, using the keywords “multiple myeloma” AND “COVID-19” AND “Prevalence OR Impact OR treatment OR prophylactic.” The included articles were review articles, recommendations, case reports or series, or population-based studies (cross-sectional, cohort, case-control, or interventional), and full-text if available. Results A total of 124 articles were identified through the search strategy. The two reviewers screened titles and abstracts of all articles. Most articles were excluded because of ineligible to the criteria. Ultimately, 18 articles were included in the final evaluation. MM patients might have higher risk to become severe COVID-19 if they got infected due to their immunocompromised condition. Due to the pandemic, precise treatment priorities should be made by considering its benefit and the risk of MM progression. For the young, especially healthy patients, the most effective therapy should be offered and tailored to the patient’s goal. Several MM societies have published the recommendation regarding the special stage of MM. Conclusion Myeloma societies in the world have released recommendations related to the management of myeloma patients. However, there is scarce of evidence to do the recommendation.

show abstract

COVID-19: impact on cancer workforce and delivery of care

Cited by 92 publications

References 0 publications

Cancer diagnosis and treatment in the COVID‐19 era

Cancer diagnosis and treatment in the COVID‐19 era

Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?

Multiple Myeloma Management in COVID-19 Era

Contact Info

Product

Resources

About